LASA — Lasa Supergenerics Share Price
0.000.00%
Last trade - 00:00- IN₹892.80m
- IN₹1.08bn
- IN₹1.04bn
- 43
- 38
- 18
- 21
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.95 | ||
| Price to Tang. Book | 1.28 | ||
| Price to Free Cashflow | 27.98 | ||
| Price to Sales | 0.68 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -12.33% | ||
| Return on Equity | -15.45% | ||
| Operating Margin | -9.67% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 1,672.71 | 2,023.8 | 1,371.27 | 1,295.68 | 1,043.35 | n/a | n/a | -9.26% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +300.27 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lasa Supergenerics Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (API) bulk drugs products. The Company is engaged in the business of manufacturing, trading, producing, processing, preparing, and treating chemicals, API, pharmaceuticals, drugs, and others. It specializes in catalyst chemistry and manufactures anthelmintic/ veterinary API products with production capabilities and product categories in India. The Company's products include API products, other API products, animal feed ingredients and reagents for therapeutic use. Its API products include Fenbendazole, Toldimphos sodium, Cyromazine, Albendazole, Riclabendazole, Rafoxanide, Ornidazole, 2,6-Diiodo-4-Nitrophenol, Ricobendazole, Oxfendazole, Closantel Base, Closantel sodium, Nitroxynil, Halquinol, and Oxyclozanide. The Company's manufacturing facility is located in Chiplun, Maharashtra.
Directors
- Omkar Herlekar CHM
- Hema Iyer CFO
- Ankita Shetty CCO
- Vishnu Gupta EDR
- Shivanand Hegde EDR
- Manali Bhagtani IND
- Ekta Gurnasinghani IND
- Ajay Sukhwani IND
- Hardesh Tolani IND
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 11th, 2016
- Public Since
- September 21st, 2017
- No. of Shareholders
- 28,250
- No. of Employees
- 77
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 50,101,239
- Address
- B/207, CITI Point, Andheri, MUMBAI, 400059
- Web
- https://lasalabs.com/
- Phone
- +91 2145232101
- Auditors
- Thanawala & Company
Upcoming Events for LASA
Q1 2026 Lasa Supergenerics Ltd Earnings Release
Lasa Supergenerics Ltd Annual Shareholders Meeting
Similar to LASA
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Lasa Supergenerics share price?
As of Today at 21:42 UTC, shares in Lasa Supergenerics are trading at IN₹17.22. This share price information is delayed by 15 minutes.
How has the Lasa Supergenerics share price performed this year?
Shares in Lasa Supergenerics last closed at IN₹17.22 and the price had moved by -33% over the past 365 days. In terms of relative price strength the Lasa Supergenerics share price has underperformed the S&P BSE 100 Index by -36.88% over the past year.
What are the analyst and broker recommendations for Lasa Supergenerics?
There is no consensus recommendation for this security.
Find out moreWhat is the Lasa Supergenerics dividend yield?
Lasa Supergenerics does not currently pay a dividend.
Does Lasa Supergenerics pay a dividend?
Lasa Supergenerics does not currently pay a dividend.
When does Lasa Supergenerics next pay dividends?
Lasa Supergenerics does not currently pay a dividend.
How do I buy Lasa Supergenerics shares?
To buy shares in Lasa Supergenerics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Lasa Supergenerics?
As of the previous close price of IN₹17.22, shares in Lasa Supergenerics had a market capitalisation of IN₹892.80m.
Where are Lasa Supergenerics shares listed?
Here are the trading details for Lasa Supergenerics:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: LASA
What kind of share is Lasa Supergenerics?
Based on an overall assessment of its quality, value and momentum Lasa Supergenerics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Lasa Supergenerics share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Lasa Supergenerics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lasa Supergenerics. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -27.49%.
As of the last closing price of IN₹17.22, shares in Lasa Supergenerics were trading -31.6% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Lasa Supergenerics PE Ratio?
The Lasa Supergenerics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹17.22.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Lasa Supergenerics?
Lasa Supergenerics' management team is headed by:
- Omkar Herlekar - CHM
- Hema Iyer - CFO
- Ankita Shetty - CCO
- Vishnu Gupta - EDR
- Shivanand Hegde - EDR
- Manali Bhagtani - IND
- Ekta Gurnasinghani - IND
- Ajay Sukhwani - IND
- Hardesh Tolani - IND